Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on BMS-986141 PK
NCT02957448Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bms-986141 in atherothrombosis, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero extrapolated to infinite time and 2 more. Started Nov 2016; status: completed.
02
Drugs
bms-986141
03
Conditions
atherothrombosis
Beyond the preview
Go deeper on NCT02957448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957448.